CAMBRIDGE, Mass., Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York.
Wells Fargo Healthcare Conference
John Butler, Chief Executive Officer, will present on Friday, September 6 at 9:30 a.m. EST.
H.C. Wainwright Global Investment Conference
Mr. Butler will participate in a fireside chat on Monday, September 9 at 10:30 a.m. EST.
A webcast of each presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conferences. A replay of the webcast will also be available for approximately 90 days following the conference through the Investors section of Akebia's website at https://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.79 |
| Daily Change: | -0.005 -0.28 |
| Daily Volume: | 407,439 |
| Market Cap: | US$375.370M |
November 14, 2024 November 07, 2024 October 22, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
